摘要
目的观察布地奈德雾化吸入治疗对急性感染性喉炎患儿炎性因子、免疫球蛋白E(IgE)水平的影响及安全性。方法将急性感染性喉炎患儿80例,按随机数字表法分为对照组及试验组,各40例。对照组将给予地塞米松1 mg·kg^-1,每天2次,静脉滴注;试验组在对照组的基础上给予布地奈德1 mg,溶解于生理盐水2 mL中,雾化吸入,初诊当天每次10 min,每30 min 1次,3 d后改为每6 h 1次,连续治疗7 d。统计2组患儿临床疗效及临床症状积分变化;以酶联免疫吸附实验(ELISA)法检测血清超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)等炎性因子水平及IgE水平;观察2组患儿治疗期间药物不良反应发生情况。结果治疗后,对照组与试验组临床总有效率分别为75.00%,95.00%,差异有统计学意义(P<0.05)。治疗后,对照组与试验组血清hs-CRP水平分别为(6.12±0.76),(2.94±0.55)mg·L^-1;TNF-α水平分别为(128.36±22.19),(82.53±17.22)ng·L^-1;IL-6水平分别为(72.38±9.45),(44.38±7.23)pg·mL^-1;IgE水平分别为(84.75±6.52),(37.24±5.18)μg·L^-1,差异均有统计学意义(均P<0.05)。与治疗前比,治疗后2组呼吸困难、声嘶、犬吠样咳嗽、哮鸣音症状评分均降低,且试验组均低于对照组(均P<0.05)。对照组与试验组药物不良反应发生率分别为15.00%,2.50%,差异有统计学意义(P<0.05)。结论布地奈德雾化吸入治疗可有效改善急性感染性喉炎患儿临床症状,有效抑制炎性因子水平及IgE分泌,提高患儿临床疗效,安全性良好。
Objective To explore the effect and safety of budesonide aerosol inhalation on the inflammatory cytokines,immunoglobulin E(IgE)level of children with acute infectious laryngitis.Methods Eighty acute infectious laryngitis children were divided into control group and treatment group,according to random number table method,40 cases in each group.Control group was treated with dexamethasone 1 mg·kg^-1,2 times per day,intravenous drip.Treatment group was treated with budesonide aerosol 1 mg dissolved into normal saline 2 mL,atomization inhalation,10 min per time on the first day,every 30 min a time,changed to every 6 h a time after 3 d,on the basis of control group,treated for continuous 7 d.The clinical effect and changes of clinical symptom score in two groups were observed.The serum inflammatory factor levels of hypersensitive C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and IgE levels were detected by enzyme-linked immunoadsorbent assay(ELISA)method;the adverse drug reactions occurred in two groups during the treatment were observed.Results The clinical effective rates after treatment in control group and treatment group were 75.00%,95.00%,with significant difference(P<0.05).After treatment,the serum hs-CRP levels in control group and treatment group were(6.12±0.76),(2.94±0.55)mg·L^-1;TNF-αlevels were(128.36±22.19),(82.53±17.22)ng·L^-1,IL-6 levels were(72.38±9.45),(44.38±7.23)pg·m L^-1;IgE levels were(84.75±6.52),(37.24±5.18)μg·L^-1,all with significant difference(all P<0.05).Compared with before treatment,the symptom scores of expiratory dyspnea,cerchnus,barking cough,wheezing rale in two groups were decreased after treatment,and treatment group were lower than those in control group(all P<0.05).The incidence of adverse drug reactions in control group and treatment group were15.00%,2.50%,with significant difference(P<0.05).Conclusion Budesonide aerosol inhalation can improve the clinical symptom of acute infectious laryngitis effectively,inhibit the inflammatory cytokines and IgE,enhance the clinical effect of children,with good safety.
作者
马克
黄尧
王开梅
MA Ke;HUANG Yao;WANG Kai-mei(Department of Pediatrics,Haikou Hospital of the Maternal and Child Health,Haikou 571100,Hainan Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2020年第10期1191-1194,共4页
The Chinese Journal of Clinical Pharmacology
关键词
急性感染性喉炎
布地奈德雾化吸入
炎性因子
免疫球蛋白E
acute infectious laryngitis
budesonide aerosol inhalation
inflammatory cytokine
immunoglobulin E
